• About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Human Metapneumovirus
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
    • Out-Licensing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Governance
    • Investor Resources
  • Contact Us

Mechanism and structural basis of small molecule inhibition of PAPD5 and PAPD7

Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer

enanta logo

©2022 Enanta Pharmaceuticals, Inc.

ENANTA PHARMACEUTICALS and accompanying logos are trademarks or registered trademarks of Enanta Pharmaceuticals, Inc.

Explore

  • About
  • Pipeline
  • Science
  • Patients
  • Careers
  • Collaborations
  • Investors
  • Contact Us

Contact

Enanta Pharmaceuticals, Inc.
Headquarters
500 Arsenal Street
Watertown, MA 02472

(617) 607-0800
info@enanta.com

Legal

  • Privacy Policy
  • Twitter Policy
  • Terms of Use
social media icon social media icon
MENU
  • About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Human Metapneumovirus
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
    • Out-Licensing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Governance
    • Investor Resources
  • Contact Us